SAN DIEGO, March 21, 2014 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative diagnostic testing and genetic analysis solutions, today announced a resolution of litigation between the Company and Paul Hawran. Mr. Hawran served as the Company's Chief Financial Officer from April 2007 until September 2009. Mr. Hawran resigned in September 2009.
After September 2009, the Securities and Exchange Commission conducted an investigation concerning alleged inaccurate disclosures by the Company in 2008 and 2009. The Securities and Exchange Commission concluded its investigation without any action against Mr. Hawran.
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genomic and genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostic markets. Website: www.sequenom.com
SOURCE Sequenom, Inc.